

## LEVETIRACETAM IV

### Supporting information

**This guideline has been prepared with reference to the following:**

NICE. Epilepsies in children, young people and adults. 2022. London. NICE

<https://www.nice.org.uk/guidance/ng217>

BNF. Levetiracetam. 2023. British National Formulary

<https://bnf.nice.org.uk/drug/levetiracetam.html>

Chamberlain JM, Kapur J, Shinnar S et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet 2020. 395:1217-24

Lyttle MD, Rainford NEA, Gamble C et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019. 393: 2125-34

European Federation of Neurological Societies. EFNS guideline on the management of status epilepticus in adults. 2009. EFNS

<https://dx.doi.org/10.1111/j.1468-1331.2009.02917.x>

**Last amended June 2024**  
**Last reviewed March 2025**